Minimally invasive treatment of tumors: The company is the first and currently the only enterprise that can provide a more complete minimally invasive comprehensive treatment solution for tumors in China. The company has successfully developed a series of professional equipments for minimally invasive treatment of tumors, which cover the main core areas of minimally invasive treatment of tumors, such as in vivo radiotherapy, radiofrequency ablation, interventional thermo-chemotherapy, extracorporeal thermotherapy, immune recovery therapy, and late-stage treatment of thoracic and abdominal fluid of tumors, etc. The interventional thermo-chemo perfusion system and the immune therapy system are both original invention products, and they have been included in the list of the first batch of recommended equipments of the State Administration of Traditional Chinese Medicine (SATCM). After the successive development of the subsequent electromagnetic positioning puncture navigation system, dual-frequency electromagnetic heat therapy machine and other products, the company will realize the coverage of self-produced equipment on the main technical fields of minimally invasive tumor treatment. At present, the company's minimally invasive tumor treatment equipment covers 155 tertiary hospitals (coverage rate of 12.57%) and 172 secondary hospitals (coverage rate of 2.64%).
Huashen Group
The company's primary liver cancer drug, iodine [131I] Metuximab Injection (Ricardin), is a national Class I innovative drug, the world's first gene-based drug using monoclonal antibody-targeted therapy for liver cancer, and the company has its own intellectual property rights for the treatment of intermediate- and advanced-stage liver cancer. Three cancer diagnosis and treatment centers have been built in cooperation.
Henkang Medical
The company invested 120 million yuan to be granted 85% of the revenue rights of the Red Cross Tumor Diagnostic and Treatment Center for 15 years. After asset evaluation of the Red Cross Cancer Clinic 15 years 85% of the operating income right evaluation value of 142 million yuan. 2012 1-11 month clinic realized net income of 31.441 million yuan. In addition, the company and the Red Cross Cancer Hospital intend to entrust the medical management of the Cancer Diagnostic and Treatment Center and the conduct of its business to Yao Yu for execution.
Cancer detection-related:
Huayu Detection
Nitrosamines are strong carcinogens and can trigger offspring tumors through the placenta and breast milk, as well as teratogenic and mutagenic effects, the company has successfully developed 11 nitrosamine substances of major concern for the detection; phosphate flame retardant has the potential carcinogenicity, teratogenicity, neurotoxicity and other toxicity, the company developed the gas chromatography - mass spectrometry technology for these five toxicities. Mass Spectrometry (GC-MS) technology for the detection of these five substances; organochlorine pesticides can cause widespread and prolonged harm to humans and animals, resulting in endocrine disruption of the human body, reproductive and immune system damage, and induce cancer and neurological disorders, for this reason, the company has developed the detection of 34 organochlorine pesticides prescribed by AAFA, and the above three technologies have reached the advanced level in the international arena.
Xilong Science
Proposed to acquire 75% of the equity of Newland Biological, Newland Biological registered capital of 20 million yuan, has developed a tumor detection reagents, total antioxidant status (TAS) test kits (FRAP method), multi-class biochemical reagents, etc., in vitro diagnostic reagent industry has a certain market scale; if the acquisition is completed, the company will enter the biochemical reagent industry, providing new growth points for the future development of the company. If the acquisition is completed, the company will enter the biochemical reagent industry, providing a new growth point for future development.
Tiger Pharmaceuticals
Tiger Pharmaceuticals mainly provides clinical research services such as phase I to IV clinical trial technical services, data management, statistical analysis, registration and other clinical research services for pharmaceutical product development. As a clinical trial CRO (contract research organization) enterprise, the company has a high level of clinical research, and is one of the few local CR O enterprises with the ability to conduct international multi-center trials. The company has also been in the leading position in the field of clinical research on innovative medicines, and has the experience of conducting clinical research on 35 Class I new medicines in a wide range of fields, such as hepatitis, oncology, endocrinology, cardio-cerebral and cerebral vascular and AIDS.
Rongzhilian
UWTech Partners with South Texas START to Launch San Antonio 1,000-Person Cancer Genome Project On September 12, 2013, a subsidiary of the world's largest genetics research organization, UW Genetics, Shenzhen UW Genome Science and Technology Service Co. ("UW Genetics"), a subsidiary of UW Genetics, the world's largest genetics research organization, and South Texas Accelerated Research Therapeutics ("START") formally announced that the two companies will jointly carry out and promote the San Antonio 1000 CAncer GEnome Project (SA1kCGP). SA1kCGP is a groundbreaking project that combines genetic variation with clinical characterization, and will further facilitate the development of personalized medicine with drug-specific markers. the SA1kCGP project is fully funded by private donations, and the genome-wide data of 10 common cancers obtained from the study will be made available free of charge to researchers around the globe. Rongzhilian's (002642) half-yearly report showed that it used its own funds of 15 million yuan to participate in Shenzhen Huada Gene Science and Technology Service Co.
Fosun Pharma
The company invested $22.4 million to subscribe for 4,299,400 shares of SALADAX's Series D preferred stock, and the company will become its single largest shareholder after the completion of this subscription. At the same time, SALADAX authorized the company's subsidiary, Fosun Changzheng, exclusive distribution rights and product manufacturing rights in China.SALADAX has the world's leading testing technology and oncology chemotherapy drug monitoring product portfolio today, through this cooperation, it will effectively enhance the company's innovation in the field of medical diagnostics, and is expected to be the first to launch a biochemical testing platform in China and even in the global market, which will be able to test the concentration of oncology chemotherapy drugs and other assays. It is expected to launch a unique biochemical testing platform in China and even in the global market, which will be able to detect the concentration of tumor chemotherapeutic drugs, etc., and thus help better analyze the therapeutic effect of tumor chemotherapeutic drugs. It is expected that this product line will form a considerable sales scale in China in the future.
Daheng Technology
The company's medical equipments include the international first-class "Whole Body Tumor 3D Stereotactic Conformal and Intensity Modulated Radiotherapy System (3DCRT, IMRT)" and the leading generation of "3D Radiation Treatment Planning System (3DTPS) and Digital Virtual Human Body Technology (VHBT)". The digital virtual human body (VHP) technology is a large-scale integrated medical device that combines computer technology, image processing technology, and radiation therapy equipment. Due to the indisputable technical level advantage of the product, it is now equipped in more than two hundred famous hospitals across the country and has the first domestic market share.
Cancer vaccine-related:
Haixin
Haixin independently researched and developed a national class I new drug, which is called "antigen-sensitized human dendritic cells (APDC)", and can be used for the treatment of rectal cancer, and is developed by Haixin Biotech (51% of which is held by the company) in cooperation with the Second Military Medical University of Shanghai. Developed by Haixin Biotech (51% of the company's shares) in cooperation with Shanghai Second Military Medical University, APDC is a national Class I new drug, and is the first independently developed APDC therapeutic vaccine for advanced colorectal cancer in China, which has been formally approved by the State Food and Drug Administration (SFDA). Haixin Bio's "Antigen Sensitized Human Dendritic Cell" (APDC) is a new generation of therapeutic tumor vaccine against colorectal cancer. (On July 26, 2012, APDC received approval from the State Food and Drug Administration to conduct Phase III clinical trials).
Watson Biologicals
Holds Shanghai Zerun (50.69% stake). Shanghai Zerun is a domestic leader in both preventive and therapeutic cervical cancer vaccine (HPV) research and development, and its recombinant HPV preventive vaccine is the first HPV vaccine in China to be developed using a eukaryotic expression system and to receive a clinical trial approval.
Jifei Bio
The company signed an agreement with Merck KGaA, an affiliate of Merck KGaA, on the "Cervical Cancer Vaccine" (HPV Vaccine), agreeing to license the company to exclusively distribute the product in the agreement area (mainland China) after the product is launched. The Merck HPV vaccine (trade name: Jadasso) is the world's first cancer vaccine and the only cancer vaccine approved for use in the prevention of cervical cancer and precancerous lesions of the reproductive organs caused by HPV types 6, 11, 16, and 18, and is currently marketed and sold in 124 countries and regions around the world.
Cancer drugs:
GuoNong Science and Technology
Huatai Pharmaceuticals, the controlling subsidiary, plans to invest a total of 213.48 million yuan in an off-site expansion of its production base in Penglai. The scale of the project is an annual output of 22 million ordinary small-volume injections, 22 million ordinary lyophilized powder injections and 10 million anti-tumor lyophilized powder injections, with a proposed construction period of 2.5 years and a production period of 1.5 years. In the long run, some of the products in the project are currently imported into the country, and now the market is better and sales are more stable.
State Pharmaceutical Consistent
The company's shareholding enterprise Wanle Pharmaceuticals (accounting for 35.19% of it) developed the anti-tumor drug doladazole.
Fengyuan Pharmaceuticals
Fengyuan Zhongren Pharmaceuticals, a joint venture between the company and Zhongren Science & Technology (in which the company holds a 60% stake), guaranteed that the new anti-cancer drug of cisplatin implant will be on the market by the end of September, 2012; and the company has vigorously invested in the research and development of the new drug of adjuvant cancer treatment.
Sihuan Bio
The company's main products include a new class of anti-cancer drugs, including recombinant human interleukin-2 for injection (used in the comprehensive treatment of kidney cancer, malignant melanoma and other malignant tumors), recombinant human interleukin-2 injection, recombinant human granulocyte-stimulating factor injection, and recombinant human erythropoietin injection, of which recombinant human interleukin-2 for injection is a national project. Recombinant human interleukin-2 for injection is an industrialized genetic engineering product of the national project "Development, pilot production and clinical application of genetically engineered human interleukin-2"; Beijing Sihuan Biological (000518) Pharmaceutical, which still holds 55% of the equity, is the earliest enterprise engaged in the research and production of genetically engineered drugs and diagnostic reagents in China, and its proprietary technologies include interleukin-2 (used in the treatment of liver cancer), interferon treatment), interferon, EPO, G-CSF and other sublingual tablets.
Hainan Haiyao Pharmaceutical
Subsidiary Haikou City Pharmaceutical Factory bendamustine is an antitumor drug with dual mechanism of action of nitrogen mustard and purine analogues, there is no bendamustine listed on the market or imported domestically, which belongs to the new drugs of chemical drugs category 3.1. Paclitaxel injection produced by the company is the first listed product in China. Paclitaxel is mainly used for first-line and second-line treatment of ovarian and breast cancers and NSCLC, and also has a certain degree of efficacy for head and neck cancers, esophageal cancers, seminoma, and relapsed non-Hodgkin's lymphoma, etc. It owns the brand name and price advantage.
Changchun Gaoxin
Changchun Jinsai Pharmaceuticals, the company's controlling subsidiary (70%), is the only national genetic engineering pharmaceutical incubation base in the country's pharmaceutical companies, its growth hormone series products have been in the country and even the Asia-Pacific region ranked first as a leader in the field of children's growth and development treatments, and in the field of burns, assisted reproduction, anti-aging, oncology, and other fields are also being established. A leading position with core competitive advantages is also being established in many fields such as burns, assisted reproduction, anti-aging and tumor. Kinsey Pharmaceuticals continues to maintain the No.1 market share of growth hormone in China.
Puluo Pharmaceuticals
Puluo Pharmaceuticals
Puluo Pharmaceuticals holds 98.07% of Zhejiang Puluokangyu Pharmaceuticals produces Baxin, which is a national Class II new antitumor drug; the company declared the "Demonstration Project for High-Technology Industrialization of Genetically Engineered Enzymatic Synthesis of D-para-Hydroxyphenyl Glycine Dungeness Potassium Salt" in the first half of 2010, which was included in the national high-tech industrialization demonstration project. Demonstration Project of High-tech Industrialization" was listed in the National High-tech Industrialization Demonstration Project. The development and construction of pharmaceuticals and R&D bases will be carried out in the Pharmaceutical Industrial Park (Second Park) in Datong Development Zone, Shanxi Province. After the completion of the project, it is expected that the production capacity will be 100 million sticks/year for aqueous injection and 20 million sticks/year for lyophilized powder injection. The total investment of the project is 25,000,000 RMB, divided into two phases. The company has completed the declaration of 4 products of cardiovascular and cerebrovascular injections, which are in the queue for review at the Drug Review Center. Meanwhile, it has completed the preliminary research of 4 special tumor injection products.
Beida Pharmaceuticals
The company cooperated with Founder Institute of Pharmaceutical Research on Compradine Disodium Phosphate (CA4P) and injection is a vascular-targeting drug or endothelium-destroying drug, whose mechanism is to cause rapid interruption of tumor blood flow supply leading to death of the tumor due to insufficient oxygenation and nutrient starvation, and the production approval of which will take about five to six years. Palonosetron hydrochloride is a second-generation 5-HT3 receptor antagonist, which is mainly used for the treatment and prevention of acute nausea and vomiting caused by moderate and severe emetogenic chemotherapy, and is mostly used as an adjuvant drug for tumors and for the prevention and treatment of nausea and vomiting after surgery. The listing of this drug will have a positive impact on the company's future performance improvement.
Huarun Sanjiu
Anhui Jinchan Biochemistry, in which the company holds 83.68% of the shares, mainly produces the anti-cancer drug Huachunin injection, which can be used for the treatment of middle- and late-stage tumors, chronic hepatitis B and other diseases.
Huabang Health
Chongqing Huabang and Chongqing Huabang Shengkai, the holding subsidiaries of the company, have received the registration approvals for "Calcium Zofolic Acid Raw Material Drugs" and "Calcium Zofolic Acid for Injection" (Chemical Drugs No. 3.1) approved by the State Food and Drug Administration. Registration approvals. Calcium levofolinate for injection is the second drug in Chongqing Huabang's oncology field, which has a positive impact on further improving the product line in the field of oncology. Clinically, levofolinic acid calcium for injection is used in combination with fluorouracil for the adjuvant treatment of gastric cancer and colorectal cancer, which can prolong the survival period. As the corresponding isomer of calcium folinate for injection, calcium levofolinate for injection has obvious advantages in efficacy and safety.
Shuanglu Pharmaceuticals
Shuanglu has been selected as one of the "Beijing Biomedical Industry Leapfrog Development Project" and one of the first batch of "Ten Hundred Thousand Project" key cultivation enterprises in Zhongguancun (9.10 +1.34%, Buy) National Innovation Demonstration Zone. In the fields of tumor therapy, anti-inflammatory and analgesic, cardiovascular, cerebrovascular and liver disease, the company has stockpiled a number of advantageous varieties with domestic and international market potential, and strives to launch more than three antibody and vaccine drugs. In the field of liver disease treatment, the company will continue to cultivate heavyweight varieties, and strive to become an important enterprise in the field of liver disease treatment in China. The company's main varieties of recombinant human granulocyte colony-stimulating factor, interleukin-11, menthyl aminotransferase, anti-tumor products and other more than 10 varieties are entering the Eastern Europe, Asia, South America market one after another.
Xinlitai
Jointly established the "Tsinghua University-Xinlitai (002294) Small Molecule Joint R&D Center" with Tsinghua University, to improve the ability to screen innovative drugs in the field of cardio-cerebral vascular, anti-tumor and other major diseases, to enhance the efficiency of research and development; the introduction of the national class 1 innovative drug It has also introduced the national Class 1 innovative drug --- Alisatan ester involving preparation production technology, and obtained the production approvals of Clopidogrel Hydrogen Sulfate Tablets 75MG, 300MG specifications and clinical approvals of Lercanidipine Tablets.
Zongsheng Pharmaceutical
Signed a tripartite technical cooperation agreement with Guangdong South China New Drug Creation Center and Sichuan University to develop new drug projects. The three projects in the first phase of development are QU100, a new chemical class I drug for pulmonary fibrosis, WCH-016, a new chemical class I drug for type II diabetes, and DXZ923, a nanoformulation for cancer.
Essence Pharmaceuticals
Research and development of the second-generation targeted anti-tumor drug betatinib: the drug has been through the synthetic route, completed the salt and crystal screening, prepared a small number of samples, and is carrying out the preliminary quality stability examination of the API.
Yuhang Pharmaceuticals
Gemcitabine hydrochloride--anti-tumor drug: Gemcitabine hydrochloride for injection belongs to the anti-metabolic tumor drug, which is widely used in the treatment of pancreatic cancer and non-small-cell lung cancer, and it is only produced by three pharmaceutical factories in China, namely Eli Lilly of the United States, Jiangsu Hausen and Yuhang Pharmaceuticals (002437).
Limex Pharmaceuticals
The company's core technologies include nano-drugs technology for lymphatic targeting therapy, micro-nano-dispersion and suspension preparation technology and sterile API preparation technology, of which the nano-drugs technology for lymphatic targeting therapy is at the leading level in the international arena; the anti-tumor drugs are mainly nano-charcoal suspension injections, fludarabine phosphate for injection, and the parenteral nutrient drugs are mainly N(2)-L -alanyl-L-glutamine injection, which fills the gaps in China and has great clinical application value. The proportion of the company's oncology drugs in the product structure will continue to improve, the company's current proportion of anti-tumor drugs is about 20%, and is expected to exceed the anti-infective drugs in three years, reaching about 40%. The company's product nano carbon suspension injection is mainly used for lymphatic tracer, its introduction as a diagnostic lymphatic tracer to fill the gaps in the country, for China's first generic drug of this type of drug, the relevant product preparation technology has been protected by the national patent, the company was the first in the world to launch the product. Fludarabine phosphate for injection is suitable for the treatment of patients with B-cell chronic lymphocytic leukemia (CLL). According to statistics, in the domestic market of fludarabine phosphate for injection, the company occupies a market share of 10.35%, and is ranked No.3 in the market.
Anke Bio
The company intends to introduce a tablet project of anti-tumor drug Tigio, a new compound anti-tumor drug mainly used for treating advanced or metastatic gastric cancer, which is expected to go into operation in 2012 with an annual production capacity of 30 million tablets.
Shang Xue Pharmaceutical
New Pharma has made an agreed payment of US$1.5 million to KINEX***. It is expected that it will take more than 5-6 years for KX02 to be developed into a new drug.In June 2013, KINEX was granted IND approval by the US FDA, and can initiate the Phase I clinical study of the complex (KX2-361) in the US after submission and modification of relevant documents. At the same time, KINEX will also start the Phase I clinical study of KX02, a lipophilic anti-tumor compound that can cross the blood-brain barrier and has a clear mechanism of action, which has been proved to be effective in inhibiting malignant glioma cells in animal experiments, and has the potential to be developed into a new and effective drug for the treatment of brain tumors.
Renfu Pharmaceutical
Hubei Gedian Renfu Pharmaceutical, in which the company holds an 81.07% stake, is a company specializing in the research and development of steroid hormone APIs, fertility-regulating drugs and antitumor drugs; Shenzhen Xinpeng Bio-engineering, in which the company holds a 52% stake, is researching and developing TR-1 drugs, a leading international anticancer gene-based drug, and it is expected to obtain the first-class new drug certificate in three to five years. The company is expected to obtain the first class new drug certificate in 3-5 years.
Taiji Group
Jointly develops 4 new drugs with independent intellectual property rights with scientific research institutes: new preparation of anticancer drug, new drug of diabetes (complications) and 2 new cardiovascular drugs, of which 2 have been granted with clinical approvals and 1 is applying for production approvals, and has independently screened 901, 902, 903, 904 and 905 new product projects. The new dosage form of DXJS, the first antitumor drug at home and abroad, has completed the process research, and the preclinical research has entered the comprehensive summary stage, and is expected to complete the clinical declaration in 2013,.
Jiangsu Wuzhong
Holding subsidiary Wuzhong Pharmaceuticals is currently researching the "national class of new biological anti-cancer drugs recombinant human vascular endothelial inhibitor injection to obtain the research and development and industrialization" project is in the application of the third phase of the clinical research phase, with independent intellectual property rights, in 2006 was awarded the national "863", the "863", the "863", the "863", the "863" and the "863". "In 2006, the project was supported by the National 863 Program for non-small cell lung cancer.
Talon Pharmaceuticals
The company has decided to take anti-tumor and cardio-cerebral vascular products as its new R&D direction in the next stage of development, and the product dosage form will be mainly in the form of small-volume injections and lyophilized powder needles.
Zhongheng Group
The company agrees to provide Peking University with not more than 100 million yuan of cooperative scientific research funds within ten years, with 10 million yuan in the first year, and then every year in accordance with the research progress and funding budget, to support it to carry out the research on early diagnosis of cancer with single-cell sequencing, and the research related to the project should be combined with the therapeutic mechanism and direction of the company's related products (such as didehydropyrimidine, etc.) for the purpose of product Promotion.
Hai Zheng Pharmaceutical
The company is China's leading manufacturer of APIs and one of the largest production bases of antibiotics and antitumor drugs in China; the company's under-construction preparation export base project has an annual production capacity of 25 million vials of cytotoxic antitumor drugs in aqueous injections, 25 million vials of lyophilized powder injections, and 160 million tablets in solid preparations; and the company's gene-based drugs, such as tumor necrosis factor receptor antibody fusion protein, have entered the phase II clinical trial stage. The company's gene drug tumor necrosis factor receptor antibody fusion protein has entered the phase II clinical trial stage.
Hengrui Medicine
The company's single-enantiomer chiral drug-calcium levofolinate can be used to enhance the anti-tumor activity of 5-fluorouracil, mainly for the treatment of osteosarcoma after high-dose methotrexate treatment and folic acid antagonism-related symptoms and colon cancer, kidney cancer; the company's a variety of anti-tumor drugs ranked No. 1 in the domestic market, of which three products are domestic Exclusive production, the existing generic drug oxaliplatin, docetaxel is in the growth period, irinotecan is also entering the rapid growth period; the company to have molecular targeting antitumor drug apatinib mesylate.
Yabao Pharmaceuticals
Anti-tumor drug injectable vincristine sulfate and other lyophilized powder needle type preparations.
Kang Enbei
The company's wholly-owned subsidiary, Hong Kong Kang Enbei (600572), the company's participation in the research and development of the Far East Super Laboratory "recombinant high-efficiency composite interferon" has obtained the first phase of the clinical trials in Singapore license, the drug is the use of protein spatial regulation technology, the successful development of a new type of non-natural interferon with a new spatial conformation, the use of protein spatial control technology. The drug is a new type of non-natural interferon with a new spatial conformation successfully developed by using protein space regulation technology, and can be used to inhibit viral replication and anti-tumor therapy. Far East Laboratories was incorporated in the British Virgin Islands on October 28, 2005, and is engaged in the research and development of cancer therapeutic drugs based on recombinant high-efficiency complex interferon (RSIFN-CO) products and technologies.
Yibai Pharmaceuticals
The company owns the anti-tumor traditional Chinese medicine Aidi injection products with gene technology, and additionally purchased the VEGI proprietary technology that can use genetic engineering methods to obtain peptide chain products, which can directly activate different types of immune cells to inhibit or eliminate cancer cells. Aidi injection research has reached the genetic level (Aidi injection for anti-tumor Chinese medicine, is the company's exclusive products) the company's first-line products Aidi for anti-tumor Chinese medicine injection exclusive varieties, revenue accounted for about 45%. Aidi in tertiary hospital sales accounted for about 80% of the sales of the variety, Lopatin for the latest listing of the third generation of platinum antitumor drugs, is the only exclusive varieties of the domestic 5 platinum antitum drugs, is currently in a period of rapid growth.
Magic Pharmaceuticals
The company's subsidiary Guizhou Jinqiao Pharmaceuticals small-volume injections (antitumor drugs) has passed the new version of the national GMP certification, yesterday has passed the publicity period. It is reported that this time through the GMP certification for the zebrano sodium injection of anti-cancer drugs. The company holds a 92.58% stake in Jinqiao Pharmaceuticals, zebrano sodium injection is suitable for primary liver cancer and other tumors, the 2013 interim report shows that zebrano sodium injection and related products constitute nearly 20% of the company's main revenue.
Harbin Pharmaceutical Company
The bioengineering company is mainly dedicated to the production and sale of medicines for tumors, cardiovascular and cerebrovascular diseases and liver diseases. Currently, the company's products include recombinant human interferon ɑ-2B for injection (trade name: Lifaneng), recombinant human erythropoietin injection (trade name: Cedarson), recombinant human granulocyte-stimulating factor injection (trade name: Riajin) and other bio-engineered products, as well as new chemical agents such as fatty milk of prostaglandin, among which recombinant human interferon ɑ-2B for injection and prostaglandin injection have the leading market share in the country. domestic market share.
Non-pharmaceutical main business involved in the concept of anti-cancer related listed companies:
Zhongzhu Holdings
Holding subsidiary Qianjiang Pharmaceuticals and the U.S. company TNI cooperation in research and development of blood, bone marrow hematopoietic system cancers and cancer patients' immunity to restore the preclinical research of anti-cancer drugs, Qianjiang Pharmaceuticals preclinical trial costs are expected to be 10 million yuan, if not passed to obtain clinical approval documents 80% of the preclinical trial expenses paid will be refunded.
Tipton Group
Tipton Pharmaceuticals, a subsidiary of the holding company, after the completion of the project to form an annual output of 35 tons of cephalosporins, antineoplastic drugs, such as raw materials production line (for the preparation of supporting) and 200 million of various types of powder injection production line. 2012 April 10 announcement, the company 99.16% of the holding of the tip of the peak of the pharmaceutical industry intends to invest 39 million yuan (according to the stage of the results of the phased payment) with the China Pharmaceutical University and its Institute of Pharmaceutical and Chemical Research and other relevant parties. University and its Institute of Pharmaceutical and Chemical Research and other relevant parties to carry out preclinical research on a new class of anti-tumor drugs (DPT).
Lansheng Stocks
The company participated in 34.65% of the shares of Lansheng Guojian Pharmaceuticals and CITIC Pacific*** invested in the establishment of "Shanghai CITIC Guojian Pharmaceuticals Co. "The new biopharmaceutical developed by CITIC Guojian (recombinant human tumor necrosis factor 11 receptor-antibody fusion protein for injection) won the second prize of the National Science and Technology Invention Award, and it is the first humanized monoclonal antibody drug that has been industrialized and marketed in China. It has completed the construction of four 750-liter cell culture production lines and successfully put them into production, with an annual production capacity of 4 million units of milligram loading.
Yatai Group
The company takes biological vaccine and anti-tumor series of drugs as the direction of new product development, and has already formed a series of anti-cancer products, such as "Ginseng capsule" and anti-cancer biological missile, and also reserves interleukin-11, ginsenoside RG3 injection and other new anti-cancer drugs under research.
Auxiliary treatment of cancer:
Zhendong Pharmaceuticals
The core leading product, Iwashu Injection, is an auxiliary treatment of cancer, which has the efficacy of inhibiting cancerous pain and hemorrhage, suppressing tumor growth, and combining with radiotherapy to increase efficiency and reduce toxicity.
Ealing Pharmaceuticals
Ealing Research Institute, a wholly-owned subsidiary of the company, has set up a pharmaceutical research center in cooperation with Cardiff University in the UK. The center will carry out in-depth exchanges and cooperation around Chinese medicine anti-tumor target research, clinical application, as well as market resources **** enjoy. It is found that Yangzheng Xiejiu Capsule can inhibit tumor neoangiogenesis, thus inhibiting tumor growth and metastasis. Nourishing and eliminating accumulation capsule is mainly used for the adjuvant treatment of tumors, and combined with chemotherapeutic drugs to help improve the efficacy of chemotherapy. Nourishing Zheng eliminating accumulation capsule with interventional therapy for primary liver cancer has remarkable efficacy in increasing the effect and reducing the toxicity, enhancing the immunity, improving the symptoms and improving the quality of life.
Haisicke
Liaoning Haisicke (002653), a subsidiary of the company, has obtained the approval of drug registration for the national Class 6 chemical drugs "Methylprednisolone Succinate" and "Methylprednisolone Sodium Succinate for Injection". Methylprednisolone is one of the most widely used adrenocorticotropic hormone drugs, which can be clinically applied to the treatment of patients with severe diseases in many departments, such as allergic diseases, malignant tumors, etc. Methylprednisolone (injection) has been approved for registration. Methylprednisolone (injection) is a Class B drug in the National Health Insurance Catalog, and the listing of this drug will enrich the company's product line and have a positive impact on the company's future performance.
Golden Flower
Transfer factor oral solution is used for the treatment of viral infections and autoimmune diseases. It is also used as adjuvant therapy for malignant tumors and tumor patients after radiotherapy.
Pientzehuang
The main ingredients of Pientzehuang (600436) include oxhuang, musk, panax notoginseng and snake gall. In addition to treating acute and chronic viral hepatitis caused by heat and blood stasis, carbuncle and furuncle, anonymous swelling and poison, bruises and all kinds of inflammation, Pientzehuang can also inhibit the growth of digestive system cancer cells, and can be used as a kind of antitumor adjuvant medicine, for which the company applies for the patent of research and development and is accepted.
Kangyuan Pharmaceuticals
Its production of pain an injection is used for the treatment of moderate and severe cancer pain of pure Chinese medicine injections, with independent intellectual property rights, the company plans to effectively promote, so that in a few years at least partially replace the opioid pain medication, to become the first-line varieties of cancer pain treatment drugs in China.